Lovesac Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lovesac Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $697.12M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $680.63M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $700.27M | Apr 2, 2026 |
| FY2023 | Jan 29, 2023 | $238.48M | Nov 30, 2023 |
| FY2023 | Oct 30, 2022 | $134.78M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $148.53M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $129.38M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $498.24M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $320.74M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | $233.38M | Mar 30, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $697.12M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $680.63M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $700.27M | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | $651.18M | Apr 10, 2025 |
| FY2024 | Jan 30, 2022 | $498.24M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $320.74M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | $233.38M | Mar 30, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $393.22M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $397.84M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $401.04M | Apr 2, 2026 |
| FY2023 | Jan 29, 2023 | $133.67M | Nov 30, 2023 |
| FY2023 | Oct 30, 2022 | $64.90M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $79.10M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $65.97M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $273.53M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $174.77M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | $116.69M | Mar 30, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $4.07M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $11.56M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $23.86M | Apr 2, 2026 |
| FY2023 | Jan 29, 2023 | $26.22M | Nov 30, 2023 |
| FY2023 | Oct 30, 2022 | ($7.36M) | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $5.85M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $1.79M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $47.49M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $14.73M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | ($15.21M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $5.36M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $13.65M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $30.08M | Apr 2, 2026 |
| FY2023 | Jan 29, 2023 | $36.48M | Nov 30, 2023 |
| FY2023 | Oct 30, 2022 | ($10.13M) | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $8.12M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $2.49M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $40.58M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $14.88M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | ($15.81M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $7.00M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $8.40M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $7.70M | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | $8.40M | Apr 10, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $283.99M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $281.45M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $264.31M | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | $215.98M | Apr 10, 2025 |
| FY2023 | Oct 30, 2022 | $53.52M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $48.82M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $44.92M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $160.02M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $111.35M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | $98.15M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $49.33M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $38.98M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $76.44M | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | ($21.38M) | Apr 10, 2025 |
| FY2023 | Oct 30, 2022 | ($68.39M) | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | ($62.89M) | Nov 30, 2023 |
| FY2023 | May 1, 2022 | ($23.33M) | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $32.65M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $40.52M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | ($11.19M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $23.14M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $21.03M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $28.74M | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | $25.24M | Apr 10, 2025 |
| FY2023 | Oct 30, 2022 | $18.12M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $9.97M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $4.45M | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | $14.62M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $8.37M | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | $10.28M | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $534.68M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $532.25M | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | $482.18M | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | $408.63M | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | $401.05M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $368.91M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $363.60M | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | $369.08M | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | $171.02M | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | $125.66M | Apr 14, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $315.98M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $315.90M | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | $264.68M | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | $215.53M | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | $241.62M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $202.72M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $202.88M | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | $211.27M | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | $63.07M | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | $35.51M | Apr 14, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $218.71M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $216.36M | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | $217.50M | Apr 2, 2026 |
| FY2026 | Jan 29, 2023 | $193.09M | Apr 2, 2026 |
| FY2023 | Oct 30, 2022 | $159.43M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $166.20M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $160.72M | Nov 30, 2023 |
| FY2025 | Jan 30, 2022 | $157.81M | Apr 10, 2025 |
| FY2024 | Jan 31, 2021 | $107.95M | Apr 11, 2024 |
| FY2021 | Feb 2, 2020 | $90.15M | Apr 14, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $144.0K | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $144.0K | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | $144.0K | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | $144.0K | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | $144.0K | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $144.0K | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $144.0K | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | $144.0K | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | $144.0K | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | $143.6K | Apr 14, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $23.86M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $25.85M | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | $34.40M | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | $10.54M | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | ($15.68M) | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | ($8.31M) | Nov 30, 2023 |
| FY2023 | May 1, 2022 | ($14.16M) | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | ($15.95M) | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | ($63.44M) | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | ($78.16M) | Apr 14, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | $101.85M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | $83.73M | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | $87.04M | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | $43.53M | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | $3.83M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | $17.65M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | $64.38M | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | $92.39M | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | $78.34M | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | $48.54M | Apr 14, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jan 31, 2021 | $78.00M | Apr 14, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | 0 | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | 0 | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | 1 | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | 1 | Apr 10, 2025 |
| FY2023 | Oct 30, 2022 | 0 | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | 0 | Nov 30, 2023 |
| FY2023 | May 1, 2022 | 0 | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | 3 | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | 1 | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | (1) | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | 0 | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | 0 | Apr 2, 2026 |
| FY2026 | Feb 4, 2024 | 1 | Apr 2, 2026 |
| FY2025 | Jan 29, 2023 | 1 | Apr 10, 2025 |
| FY2023 | Oct 30, 2022 | 0 | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | 0 | Nov 30, 2023 |
| FY2023 | May 1, 2022 | 0 | Nov 30, 2023 |
| FY2024 | Jan 30, 2022 | 2 | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Nov 30, 2023 |
| FY2022 | Feb 2, 2020 | (1) | Mar 30, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 1, 2026 | 14.62M | Apr 2, 2026 |
| FY2026 | Feb 2, 2025 | 14.79M | Apr 2, 2026 |
| FY2025 | Feb 4, 2024 | 15.49M | Apr 10, 2025 |
| FY2024 | Jan 29, 2023 | 15.20M | Apr 11, 2024 |
| FY2023 | Oct 30, 2022 | 15.19M | Nov 30, 2023 |
| FY2023 | Jul 31, 2022 | 15.18M | Nov 30, 2023 |
| FY2023 | May 1, 2022 | 15.13M | Nov 30, 2023 |
| FY2023 | Jan 30, 2022 | 15.12M | Nov 30, 2023 |
| FY2022 | Jan 31, 2021 | 15.01M | Mar 30, 2022 |
| FY2021 | Feb 2, 2020 | 14.47M | Apr 14, 2021 |